Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Importance of Multidisciplinary Thyroid Cancer Care

July 9th 2014

Treatment Selection in Advanced MTC

July 9th 2014

Utilizing TKIs in Advanced Medullary Thyroid Cancer

July 9th 2014

Diagnosis and Initial Treatment of MTC

July 9th 2014

Managing Sorafenib-Related AEs in Thyroid Cancer

July 9th 2014

Case Study: Treating Papillary Thyroid Cancer

July 9th 2014

Role of the Endocrinologist in RAI-Refractory Thyroid Cancer

July 9th 2014

Patient Selection for Systemic Therapy in DTC

July 9th 2014

Sequencing Therapies in Differentiated Thyroid Cancer

July 9th 2014

Available Treatment Options for RAI-Refractory DTC

July 9th 2014

Determining Treatment for RAI-Refractory Thyroid Cancer

July 9th 2014

Introduction: Radioactive Iodine-Refractory DTC

July 9th 2014

Dr. Ilson Discusses the Findings of the RTOG 0436 Trial

July 8th 2014

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the conclusions of the RTOG 0436 trial, a phase III trial of cisplatin, paclitaxel, and radiation with or without cetuximab in the non-operative treatment of esophageal cancer.

Dacomitinib Shows Promise in Head and Neck Cancer

July 7th 2014

Dacomitinib holds promise for the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

Docetaxel May Cause Intoxication, FDA Warns

June 20th 2014

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

Dr. Schlumberger Draws Conclusions From the SELECT Trial in Thyroid Cancer

June 17th 2014

Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.

FDA Approves Lymphoseek for Head and Neck Cancer

June 13th 2014

The FDA has approved the radioactive diagnostic imaging agent Lymphoseek (technetium 99m tilmanocept) Injection to guide sentinel lymph node biopsy in patients with cancer of the head and neck.

Lenvatinib Likely to Become Standard in Resistant Differentiated Thyroid Cancer

May 31st 2014

Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.

Study Supports Dialing Back Radiation for Some Patients With HPV-Positive Oropharyngeal Cancer

May 31st 2014

Patients with less aggressive, HPV-positive oropharyngeal cancer can be effectively treated with a lower-dose radiation regimen depending upon their response to combination induction therapy.

Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers

May 27th 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.